Global Antiviral Therapeutics Market Report 2016 - Profiles of 192 Companies With 172 Collaborations - Research and Markets

DUBLIN, April 5, 2016 /PRNewswire/ --

Research and Markets has announced the addition of Jain PharmaBiotech's new report, "Antiviral Therapeutics - Technologies, Markets and Companies," to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO )

This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts with a practical classification of viral diseases according to their commercial importance. Various antiviral approaches are described including pharmaceuticals and molecular biological therapies such as gene therapy and RNA interference (RNAi) as well as vaccines for virus infections. Expert opinion is given about the current problems and needs in antiviral therapy. SWOT (strengths, weaknesses, opportunities and threats) analysis of antiviral approaches is presented against the background of concept of an ideal antiviral agent. 

A novel feature of this report is the use of nanotechnology in virology and its potential for antiviral therapeutics. Interaction of nanoparticles with viruses are described. NanoViricides are polymeric micelles, which act as nanomedicines to destroy viruses. Various methods for local as well as systemic delivery of antiviral agents and vaccines are described. Nanobiotechnology plays an important role in improving delivery of antivirals. Advantages and limitations of delivery of gene-based, antisense and RNAi antiviral therapeutics are discussed. 

Markets for antivirals are considered according to viruses and diseases caused by them and also according to management approaches: antiviral drugs, vaccines, MAbs and innovative approaches that include immunological and use of other technologies such as gene therapy, antisense, RNAi and nanobiotechnology. Antiviral markets are estimated starting with 2015 with projections up to the year 2025. 

Profiles of 192 companies that are involved in developing various technologies and products are profiled and with 172 collaborations. These include major pharmaceutical companies (12), Biopharmaceutical companies with antiviral products (84), Antiviral drug companies (26) as well as viral vaccine companies (70). The report is supplemented with 52 tables, 13 figures and 540 references from the literature. 

Key Topics Covered: 

Executive Summary 

1. Introduction to Virology 

2. Antiviral Approaches 

3. Vaccines for Virus Infections 

4. Role of Nanotechnology in Developing Antiviral Agents 

5. Delivery of Antivirals 

6. Competitive Assessment of Antiviral Approaches 

7. Influenza Viruses 

8. AIDS/HIV 

9. Hepatitis Viruses 

10. Miscellaneous Commercially Important Virus Infections 

11. Viruses with High Impact but Low Commercial Significance 

12. Markets for Antivirals 

13. Companies 

14. References 

For more information visit http://www.researchandmarkets.com/research/2ppvfh/antiviral 

Source: Jain PharmaBiotech

Media Contact: 

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716